La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Globus Medical Croissance future

Future contrôle des critères 3/6

Globus Medical devrait augmenter ses bénéfices et son chiffre d'affaires de 53.3% et de 8.4% par an respectivement. Le BPA devrait croître de de 53% par an. Le rendement des capitaux propres devrait être 10.7% dans 3 ans.

Informations clés

53.3%

Taux de croissance des bénéfices

53.0%

Taux de croissance du BPA

Medical Equipment croissance des bénéfices	17.8%
Taux de croissance des recettes	8.4%
Rendement futur des capitaux propres	10.7%
Couverture par les analystes	Good
Dernière mise à jour	15 Aug 2024

Mises à jour récentes de la croissance future

Recent updates

Globus Medical: A Post Acquisition Analysis

Aug 26

Globus Medical, Inc.'s (NYSE:GMED) Earnings Haven't Escaped The Attention Of Investors

Jun 28

An Intrinsic Calculation For Globus Medical, Inc. (NYSE:GMED) Suggests It's 42% Undervalued

Apr 08

Globus Medical Non-GAAP EPS of $0.50 misses by $0.02, revenue of $254.15M in-line

Nov 08

A Look At The Fair Value Of Globus Medical, Inc. (NYSE:GMED)

Oct 15

Globus Medical: Compelling Long-Term Value On Offer, Buy Thesis Intact

Sep 02

Globus Medical (NYSE:GMED) Will Be Hoping To Turn Its Returns On Capital Around

Sep 02

Is Globus Medical, Inc. (NYSE:GMED) Potentially Undervalued?

Aug 11

Globus Medical: Low Rates Sensitivity, Seeking 26% Return Objective

Jun 05

Globus Medical (NYSE:GMED) May Have Issues Allocating Its Capital

May 24

Is It Too Late To Consider Buying Globus Medical, Inc. (NYSE:GMED)?

May 06

Prévisions de croissance des bénéfices et des revenus

NYSE:GMED - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	2,845	441	N/A	N/A	10
12/31/2025	2,656	384	692	N/A	14
12/31/2024	2,484	124	34	N/A	13
6/30/2024	2,237	41	161	262	N/A
3/31/2024	1,898	67	152	243	N/A
12/31/2023	1,568	123	165	243	N/A
9/30/2023	1,226	158	129	203	N/A
6/30/2023	1,097	204	121	185	N/A
3/31/2023	1,069	201	117	187	N/A
12/31/2022	1,023	190	104	178	N/A
9/30/2022	998	155	118	191	N/A
6/30/2022	974	155	157	235	N/A
3/31/2022	961	142	194	257	N/A
12/31/2021	958	149	219	276	N/A
9/30/2021	942	187	226	280	N/A
6/30/2021	928	184	203	256	N/A
3/31/2021	826	122	165	220	N/A
12/31/2020	789	102	135	199	N/A
9/30/2020	767	95	108	173	N/A
6/30/2020	747	89	115	176	N/A
3/31/2020	793	148	110	175	N/A
12/31/2019	785	155	101	172	N/A
9/30/2019	770	146	90	162	N/A
6/30/2019	743	143	82	158	N/A
3/31/2019	722	150	93	169	N/A
12/31/2018	713	156	122	182	N/A
9/30/2018	693	144	126	182	N/A
6/30/2018	676	134	112	165	N/A
3/31/2018	655	118	N/A	158	N/A
12/31/2017	636	107	N/A	159	N/A
9/30/2017	612	107	N/A	166	N/A
6/30/2017	595	108	N/A	174	N/A
3/31/2017	581	105	N/A	171	N/A
12/31/2016	564	104	N/A	148	N/A
9/30/2016	553	118	N/A	166	N/A
6/30/2016	554	118	N/A	153	N/A
3/31/2016	548	116	N/A	143	N/A
12/31/2015	537	113	N/A	124	N/A
9/30/2015	518	103	N/A	80	N/A
6/30/2015	499	99	N/A	85	N/A
3/31/2015	481	96	N/A	85	N/A
12/31/2014	467	92	N/A	79	N/A
9/30/2014	454	86	N/A	110	N/A
6/30/2014	443	83	N/A	108	N/A
3/31/2014	436	70	N/A	104	N/A
12/31/2013	427	69	N/A	93	N/A
9/30/2013	420	68	N/A	86	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de GMED ( 53.3% par an) est supérieure au taux d'épargne ( 2.5% ).

Bénéfices vs marché: Les bénéfices de GMED ( 53.3% par an) devraient croître plus rapidement que le marché US ( 15.1% par an).

Croissance élevée des bénéfices: Les bénéfices de GMED devraient augmenter de manière significative au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de GMED ( 8.4% par an) devrait croître plus lentement que le marché de US ( 8.8% par an).

Croissance élevée des revenus: Le chiffre d'affaires de GMED ( 8.4% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de GMED devrait être faible dans 3 ans ( 10.7 %).

Globus Medical Croissance future

Future contrôle des critères 3/6

Informations clés

Mises à jour récentes de la croissance future

Consensus EPS estimates fall by 46%

Globus Medical, Inc. Revises Earnings Guidance for the Year 2024

Price target increased by 7.8% to US$70.42

Globus Medical, Inc. Updates Earnings Guidance for the Full Year 2024

Consensus EPS estimates fall by 21%

Globus Medical, Inc. Reaffirms Revenue Guidance for the Full Year 2024

Recent updates

Globus Medical: A Post Acquisition Analysis

Globus Medical, Inc. Launches ADIRA™? XLIF™? Plate System

Consensus EPS estimates fall by 46%

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Globus Medical, Inc. Revises Earnings Guidance for the Year 2024

Globus Medical, Inc. Receives FDA 510(k) Clearance for Excelsiusflex™? and ACTIFY™? 3D Total Knee System

Globus Medical, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Globus Medical, Inc.(NYSE:GMED) dropped from Russell 1000 Value-Defensive Index

Globus Medical, Inc.'s (NYSE:GMED) Earnings Haven't Escaped The Attention Of Investors

Price target increased by 7.8% to US$70.42

Independent Director recently sold US$698k worth of stock

Globus Medical, Inc. Updates Earnings Guidance for the Full Year 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Globus Medical, Inc., Annual General Meeting, Jun 05, 2024

Globus Medical, Inc. to Report Q1, 2024 Results on May 07, 2024

An Intrinsic Calculation For Globus Medical, Inc. (NYSE:GMED) Suggests It's 42% Undervalued

Globus Medical (NYSE:GMED) Seems To Use Debt Rather Sparingly

Director notifies of intention to sell stock

Senior VP notifies of intention to sell stock

Consensus EPS estimates fall by 21%

Globus Medical Q4: Greater Dis-Synergies Hold Back The Stock

Full year 2023 earnings: EPS misses analyst expectations

Globus Medical, Inc. Reaffirms Revenue Guidance for the Full Year 2024

Is Now An Opportune Moment To Examine Globus Medical, Inc. (NYSE:GMED)?

Globus Medical Promotes Keith Pfeil to Chief Operating Officer

Globus Medical, Inc.'s (NYSE:GMED) Price In Tune With Earnings

Globus Medical, Inc. to Report Q4, 2023 Results on Feb 20, 2024

Globus Medical: Merger Overhang Lingering

Does Globus Medical (NYSE:GMED) Have A Healthy Balance Sheet?

Consensus EPS estimates fall by 32%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Globus Medical, Inc. Revises Earnings Guidance for the Year 2023

Should You Investigate Globus Medical, Inc. (NYSE:GMED) At US$46.27?

Globus Medical, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Globus Medical: Almost Having My Back

New minor risk - Shareholder dilution

Globus Medical, Inc. (NYSE:GMED) completed the acquisition of NuVasive, Inc. (NasdaqGS:NUVA) from BlackRock, Inc. (NYSE:BLK), The Vanguard Group, Inc., Thrivent Financial for Lutherans and others.

Globus Medical: Slightly Too Pricey Right Now

Globus Medical, Inc. Updates Earnings Guidance for the Year 2023

Second quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Globus Medical, Inc. Announces Launch of the Marvel(Tm) Growing Rod System

Globus Medical: Robotics Demand Ratcheting Higher, Reiterate Buy

Globus Medical, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Should You Think About Buying Globus Medical, Inc. (NYSE:GMED) Now?

Globus Medical, Inc.(NYSE:GMED) dropped from Russell 1000 Growth-Defensive Index

Here's Why We Think Globus Medical (NYSE:GMED) Is Well Worth Watching

Independent Director exercised options and sold US$1.4m worth of stock

Globus Medical, Inc. Provides Earnings Guidance for the Full Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Globus Medical (NYSE:GMED) Will Be Hoping To Turn Its Returns On Capital Around

What Is Globus Medical, Inc.'s (NYSE:GMED) Share Price Doing?

Do Globus Medical's (NYSE:GMED) Earnings Warrant Your Attention?

Full year 2022 earnings: EPS misses analyst expectations

Globus Medical Q4 2022 Earnings Preview

Independent Director exercised options to buy US$334k worth of stock.

Price target decreased by 7.3% to US$72.58

Globus Medical, Inc. (NYSE:GMED) entered into a definitive agreement to acquire NuVasive, Inc. (NasdaqGS:NUVA) for $3.1 billion.

Investor sentiment deteriorates as stock falls 20%

Senior VP & CFO exercised options and sold US$760k worth of stock

Globus Medical, Inc. to Report Q4, 2022 Results on Feb 21, 2023

Independent Director exercised options to buy US$566k worth of stock.

Globus Medical: An Impressive Long-Term Revenue Growth Play

Insufficient new directors

Is It Too Late To Consider Buying Globus Medical, Inc. (NYSE:GMED)?

Senior VP exercised options and sold US$468k worth of stock

Globus Medical (NYSE:GMED) Will Want To Turn Around Its Return Trends

Third quarter 2022 earnings: EPS misses analyst expectations

Globus Medical, Inc. Reaffirms Net Sales Guidance for the Year 2022

Globus Medical Non-GAAP EPS of $0.50 misses by $0.02, revenue of $254.15M in-line